Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $5.5K in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value |
|---|
Company profile
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Shares total |
|---|
| SEC Form 4 |
|---|
| Saccomano Nicholas A | President and CEO | Jun 22 '26 | Sale | $4.40 | 86 | $378 | 11,247 | Jun 24 07:29 PM |
| Leverone Jason A. | Chief Financial Officer | Jun 22 '26 | Sale | $4.40 | 303 | $1,332 | 18,802 | Jun 24 07:27 PM |
| Saccomano Nicholas A | President and CEO | Mar 23 '26 | Sale | $4.16 | 86 | $357 | 7,333 | Mar 24 06:57 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.